Cancer Treat Rev. 2008 Feb;34(1):92-101. Epub 2007 Oct 26.

RANK ligand as a therapeutic target for bone metastases and multiple myeloma.

Source

University of Pittsburgh School of Medicine and VA Medical Center, VA Pittsburgh Healthcare System, Research and Development (151-U), Pittsburgh, PA 15240, USA. roodmangd@upmc.edu

Abstract

Osteoclastic bone resorption is a critical component of skeletal complications of malignancy including fracture, bone pain, hypercalcemia, and spinal cord compression. Three proteins, RANKL, RANK, and OPG have been recently identified as key determinants of osteoclastogenesis and the regulation of bone resorption. Both RANKL and OPG can be aberrantly regulated in the cancer setting and function as important gatekeepers of tumor-induced osteolytic bone disease. RANKL-induced osteoclastogenesis not only mediates osteolytic bone disease, but also contributes to the pathogenesis of osteoblastic bone disease resulting from tumors. In addition, an important role was recently described for bone marrow derived RANKL to mediate the bone-specific tropism of RANK-expressing tumor cells. This manuscript will review how RANKL contributes to skeletal complications of cancer and the development of targeted, mechanism-based drugs that inhibit RANKL.

PMID:: 17964729; [PubMed - indexed for MEDLINE]

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Supplemental Content

Save items

Related citations in PubMed

Review The RANK/RANKL/OPG triad in cancer-induced bone diseases. [Cancer Metastasis Rev. 2006]
Review The RANK/RANKL/OPG triad in cancer-induced bone diseases.
Dougall WC, Chaisson M. Cancer Metastasis Rev. 2006 Dec; 25(4):541-9.
Review RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis. [Biochim Biophys Acta. 2004]
Review RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis.
Wittrant Y, Théoleyre S, Chipoy C, Padrines M, Blanchard F, Heymann D, Rédini F. Biochim Biophys Acta. 2004 Sep 20; 1704(2):49-57.
Review RANKL signaling in bone physiology and cancer. [Curr Opin Support Palliat Care...]
Review RANKL signaling in bone physiology and cancer.
Dougall WC. Curr Opin Support Palliat Care. 2007 Dec; 1(4):317-22.
Review Targeting the receptor activator of nuclear factor-kappaB (RANK) ligand in prostate cancer bone metastases. [BJU Int. 2008]
Review Targeting the receptor activator of nuclear factor-kappaB (RANK) ligand in prostate cancer bone metastases.
Saad F, Markus R, Goessl C. BJU Int. 2008 May; 101(9):1071-5. Epub 2007 Dec 5.
Review Bone lesions in multiple myeloma--the OPG/RANK-ligand system. [Folia Med (Plovdiv). 2004]
Review Bone lesions in multiple myeloma--the OPG/RANK-ligand system.
Goranov SE, Goranova-Marinova VS. Folia Med (Plovdiv). 2004; 46(3):5-11.

See reviews... See all...

Cited by 7 PubMed Central articles

Dasatinib as a bone-modifying agent: anabolic and anti-resorptive effects. [PLoS One. 2012]
Dasatinib as a bone-modifying agent: anabolic and anti-resorptive effects.
Garcia-Gomez A, Ocio EM, Crusoe E, Santamaria C, Hernández-Campo P, Blanco JF, Sanchez-Guijo FM, Hernández-Iglesias T, Briñón JG, Fisac-Herrero RM, et al. PLoS One. 2012; 7(4):e34914. Epub 2012 Apr 23.
Review Bone metastasis: mechanisms and therapeutic opportunities. [Nat Rev Endocrinol. 2011]
Review Bone metastasis: mechanisms and therapeutic opportunities.
Suva LJ, Washam C, Nicholas RW, Griffin RJ. Nat Rev Endocrinol. 2011 Apr; 7(4):208-18. Epub 2011 Jan 4.
Combined inhibition of the BMP pathway and the RANK-RANKL axis in a mixed lytic/blastic prostate cancer lesion. [Bone. 2011]
Combined inhibition of the BMP pathway and the RANK-RANKL axis in a mixed lytic/blastic prostate cancer lesion.
Virk MS, Alaee F, Petrigliano FA, Sugiyama O, Chatziioannou AF, Stout D, Dougall WC, Lieberman JR. Bone. 2011 Mar 1; 48(3):578-87. Epub 2010 Nov 10.

See all...

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

RANK ligand as a therapeutic target for bone metastases and multiple myeloma.
RANK ligand as a therapeutic target for bone metastases and multiple myeloma.
Cancer Treat Rev. 2008 Feb ;34(1):92-101. Epub 2007 Oct 26 .

PubMed
Genetic dissection of myopia: evidence for linkage of ocular axial length to chr...
Genetic dissection of myopia: evidence for linkage of ocular axial length to chromosome 5q.
Ophthalmology. 2008 Jun ;115(6):1053-1057.e2. Epub 2007 Oct 26 .

PubMed
TY3 GAG3 protein forms ordered particles in Escherichia coli.
TY3 GAG3 protein forms ordered particles in Escherichia coli.
Virology. 2008 Jan 20 ;370(2):223-7. Epub 2007 Oct 26 .

PubMed
Neuroprotection and repair.
Neuroprotection and repair.
J Neurol Sci. 2008 Feb 15 ;265(1-2):21-5. Epub 2007 Oct 26 .

PubMed
Redox-dependent impairment of vascular function in sickle cell disease.
Redox-dependent impairment of vascular function in sickle cell disease.
Free Radic Biol Med. 2007 Dec 1 ;43(11):1469-83. Epub 2007 Aug 31 .

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to:

RANK ligand as a therapeutic target for bone metastases and multiple myeloma.

Source

Abstract

Publication Types, MeSH Terms, Substances

Publication Types

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Supplemental Content

Save items

Related citations in PubMed

Cited by 7 PubMed Central articles

Related information

Recent activity

Simple NCBI Directory

Getting Started

Resources

Popular

Featured

NCBI Information